TargetBeta
TACR3
tachykinin receptor 3 · also NK3R, NKR, TAC3R · Tachykinin receptors
3 programs in company-led studies act on TACR3, from 3 companies: 2 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| fezolinetantrule | Astellas Pharma | antagonist | phase 3 | 213 running | – | NCIt |
| elinzanetantrule | Bayer | antagonist | phase 3 | 242 running | TAC3, TACR1 | NCIt |
| GS1-144rule | Changchun GeneScience Pharmaceutical | antagonist | phase 2 | 62 running | – | the studies' text |
Conditions their studies are in
- Hot Flashes, 2 programs
- Prostatic Neoplasms, 1 program
- Renal Insufficiency, 1 program
- Schizophrenia, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jan 22, 2027elinzanetant · Bayer · phase 3 · NCT07762287
- Jan 31, 2027GS1-144 · Changchun GeneScience Pharmaceutical · phase 2 · NCT07491289
- Apr 30, 2027fezolinetant · Astellas Pharma · phase 3 · NCT07783282
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.